COMMUNIQUÉS West-GlobeNewswire

-
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
11/06/2025 -
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
11/06/2025 -
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
11/06/2025 -
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
11/06/2025 -
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
11/06/2025 -
AGM Update
11/06/2025 -
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
11/06/2025 -
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
11/06/2025 -
Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
11/06/2025 -
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
11/06/2025 -
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
11/06/2025 -
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
11/06/2025 -
Ocugen To Present at BIO International Convention 2025
11/06/2025 -
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
11/06/2025 -
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
11/06/2025 -
ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601
11/06/2025 -
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
11/06/2025 -
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
11/06/2025 -
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
11/06/2025
Pages